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atching the Watchman*
eter C. Block, MD, FACC
tlanta, Georgia
e know that the risk of stroke is increased in patients with
trial fibrillation (AF), presumably because stagnant blood
ow within the left atrium leads to thrombus formation.
mportantly, 90% of thrombi, when seen by echocardiogra-
hy in patients with nonrheumatic AF, are located in the
eft atrial appendage (LAA) (1,2). Standard treatment of
atients with AF is anticoagulation with warfarin. If war-
arin is not tolerated, aspirin and possibly clopidogrel are
sed. Despite such therapy, stroke still occurs in patients
ith AF, and evaluation of alternative strategies to mini-
ize thromboembolic risk makes sense.
See page 1490
The concept of excluding the LAA from the circulation
n patients with AF is not new. When surgery is performed
or rheumatic mitral valve disease, which is often accompa-
ied by AF, LAA amputation or oversewing of its orifice is
outinely done to minimize the risk of future thromboem-
olism. Minimally invasive transthoracic techniques also
ave been used to achieve the same result with mixed
utcomes—suturing the LAA either from within or without
ay occlude the orifice of the LAA but persistent flow into
nd out of the LAA is frequently seen when such patients
ave echocardiograms at follow-up. In the last 5 years,
ercutaneous transcatheter devices to exclude the LAA
rom the circulation have made their debut. The question
emains whether such devices can be as effective as standard
nticoagulation therapy.
The first transcatheter LAA occlusion device placed via a
rans-septal approach (PLAATO System, ev3 Inc., Ply-
outh, Minnesota) has already been tested in a phase I
linical trial. That study, reported in the Journal in 2005 (3),
stablished that a transcatheter LAA occlusive device could
e implanted with acceptable risk, and raised the possibility
hat patients in AF with contraindications for warfarin
herapy might have other treatment options. The PLAATO
ystem Trial included only patients with nonrheumatic AF
ho were at high risk for ischemic stroke and who were not
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thel
merican College of Cardiology.
From the Emory University Hospital, Department of Cardiology, Atlanta, Georgiaandidates for long-term anticoagulation with warfarin. To
e eligible they were required to have a history of transient
schemic attack (TIA) or stroke and at least 1 (in Europe) or
(in North America) of the following risk factors: conges-
ive heart failure, systolic hypertension, diabetes, age 65
ears, coronary artery disease, and spontaneous echocardi-
graphy contrast or blood flow velocity20 cm/s within the
AA. The group predicted stroke risk based on the patients’
djusted CHADS score (4) distribution was 6.3% per year,
onfirming the treated patients’ high-risk status. We learned
rom that trial that transcatheter implantation of a device to
cclude the LAA was feasible, reasonably safe (9
rocedural-related adverse events, of which pericardial ef-
usion [2 patients] and tamponade [2 patients] were the
ost significant), and raised the possibility that the inci-
ence of stroke after PLAATO implantation was reduced.
he actual stroke rate in the study was 4.1%/year. A later
eport (5) indicated that the actual stroke rate in a larger
roup of PLAATO patients was reduced to 3.2% (a relative
isk reduction of about 50%). No comparison control
atients were included in either report, so that the signifi-
ance of the outcomes can only be surmised. Despite these
romising data, no phase II trial of the PLAATO System is
urrently planned.
In this issue of the Journal (6), we now have information
n another LAA occlusion device, the WATCHMAN
ystem developed by Atritech Inc., Plymouth, Minnesota.
t too demonstrates that percutaneous LAA occlusion can
e performed with reasonable safety and efficacy. The
umbers are small, but 54 of 58 patients with devices seen
t 45-day follow-up had successful sealing of the LAA. Two
atients had TIAs at follow-up, but there were no strokes at
mean follow-up of 24  11 months, and 33 patients have
een followed for more than 3 years.
What can we take away from these preliminary trials?
ost importantly, they demonstrate that percutaneous
rans-septal placement of an LAA occlusion device can be
one safely and produce a high degree of LAA orifice
ealing. However, a comparison of the 2 trials, or combining
he results to try and understand outcomes with larger
umbers, is not appropriate.
First, the 2 trial designs and the devices themselves are
uite different. The PLAATO System is a self-expanding
itinol cage covered with expanded polytetrafluoroethylene
hat excludes blood from entering the LAA. Post-
mplantation treatment of patients in that trial consisted of
nly clopidogrel and aspirin initially and long-term aspirin
lone. In contrast, the WATCHMAN System is a nitinol
rame structure covered with a permeable polyester fabric
hat allows blood flow but excludes passage of thrombi out
f the LAA. Thus, patients who cannot take warfarin
ecause of bleeding or other problems are not candidates for
ATCHMAN implantation because anticoagulation for
5 days to 6 months is necessary by protocol until endothe-
ialization of the device is complete. In the PLAATO trial,
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April 3, 2007:1496–7 Editorial Commenthe population of patients potentially treatable with that
evice was restricted to non-warfarin candidates. Thus, the
trial populations are quite disparate. There is, however,
othing specific to the polyester-covered WATCHMAN
evice that demands warfarin anticoagulation. Instead, what
he WATCHMAN phase I trial tested and now promises is
hat the population of patients potentially treatable with this
evice is far larger, and might include any patient with AF
hat would prefer implantation of an LAA occlusion device
lus long-term aspirin therapy to long-term warfarin
herapy.
Second, the patients treated in the WATCHMAN
eport are lower risk. Their average CHADS score was 1.8
1.1 compared with the PLAATO group’s 2.5  1.3.
hus, the anticipated stroke rate in the WATCHMAN
opulation would predictably be low, and perhaps the lack
f any strokes in this phase I trial is due to this fact as well
s the small number of patients enrolled.
Third, both the PLAATO and WATCHMAN trials
emonstrate that new devices, particularly those placed via
rans-septal puncture, are tricky, and a learning curve
oncerning implantation is inevitable. Pericardial effusion/
amponade occurred in both trials, and device embolization
n the first generation of the WATCHMAN device
rompted a design change. There is still no free lunch.
Lastly, where do these feasibility trials take us? We can
onclude little more than relative safety and feasibility of
ranscatheter occlusion of the LAA. The temptation to
mphasize the reduction in anticipated stroke rate is appeal-
ng, but, without a control group of patients, that conclusion
s not reliable. What we need is a prospective, randomized
rial of either (or both) devices. The WATCHMAN
ystem is now being tested in exactly that manner. The
esign is straightforward. There is a 2:1 randomization
gainst standard warfarin anticoagulation, and those pa-
ients receiving the device will have warfarin for 45 days (or
p to 6 months if needed) until endothelialization of the
evice is complete. Presumably, some patients in the trial
ill not be able to tolerate warfarin for the required time,
nd we may learn something about the outcome of reduced
arfarin therapy with the device in place. However, I suspect
hat patient numbers in this subgroup will be small, thereby
aking difficult or impossible any conclusions about reducing
he length of time warfarin is needed after implantation.To be eligible patients must be 18 years of age or older,
ave chronic or paroxysmal nonvalvular AF, be eligible for
ong-term warfarin therapy, be eligible to discontinue war-
arin therapy if the LAA is sealed, and have a CHADS
core of 1 or greater. The trial is designed to show that the
reatment arm is not inferior to the control arm so that if the
rial is successful, we may be able to tell our patients that
lacement of a WATCHMAN device is at least equivalent
o standard warfarin therapy. My guess is that since the
atients in the trial are relatively low risk, the number of
atients reaching end points will be5% per year. This may
ake comparisons difficult. The good news is that if the
rial shows equivalence, we will have the option of advising
ur patients that long-term use of warfarin, especially in
ounger patients with AF or in patients who have problems
n maintaining appropriate international normalized ratio
evels on warfarin, can be avoided. We all need to watch the
ATCHMAN—the strategies available for treatment of
atients with AF to prevent thromboembolism may well
ncrease.
eprint requests and correspondence: Dr. Peter C. Block,
mory University Hospital, Cardiology, 1364 Clifton Road NE,
uite 606, Atlanta, Georgia 30322. E-mail: Peter.block@
moryhealthcare.org.
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